Q4 2023 13F Holders as of 31 Dec 2023
-
Type / Class
-
Equity / Common Stock and Warrants
-
Shares outstanding
-
55,095,630
-
Total 13F shares
-
20,391,503
-
Share change
-
+459,392
-
Total reported value
-
$417,920,110
-
Price per share
-
$20.49
-
Number of holders
-
51
-
Value change
-
+$9,592,150
-
Number of buys
-
31
-
Number of sells
-
12
Institutional Holders of AN2 Therapeutics, Inc. - Common Stock and Warrants (ANTX) as of Q4 2023
As of 31 Dec 2023,
AN2 Therapeutics, Inc. - Common Stock and Warrants (ANTX) was held by
51 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
20,391,503 shares.
The largest 10 holders included
RA CAPITAL MANAGEMENT, L.P., TCG Crossover Management, LLC, BVF INC/IL, CITADEL ADVISORS LLC, Frazier Life Sciences Management, L.P., JANUS HENDERSON GROUP PLC, Avidity Partners Management LP, VANGUARD GROUP INC, ADAGE CAPITAL PARTNERS GP, L.L.C., and Octagon Capital Advisors LP.
This page lists
51
institutional shareholders reporting positions in this security
for the Q4 2023 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.